USD 0.6533
↓ -0.0405 (-5.84%)
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| COSM | -5.8 | -4.1 | -11.0 | -40.1 | -12.8 | -34.7 | -99.3 | -99.0 | -99.7 | -99.8 |
| S&P 500 | -0.6 | -0.5 | 1.5 | 9.1 | 13.4 | 32.3 | 27.0 | 92.1 | 191.7 | 33587.3 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | COSM |
| name | Cosmos Health Inc. |
| price | 0.6533 |
| changes percentage | -5.8374 |
| change | -0.0405 |
| day low | 0.54 |
| day high | 0.69 |
| year high | 1.65 |
| year low | 0.468 |
| market cap | 15195497 |
| price avg 50 | 0.84524 |
| price avg 200 | 0.856505 |
| exchange | NASDAQ |
| volume | 236941 |
| avg volume | 510123 |
| open | 0.69 |
| previous close | 0.6938 |
| eps | -2.1 |
| pe | -0.31 |
| earnings announcement | 2024-11-19T12:00:00.000+0000 |
| shares outstanding | 23259600 |
| timestamp | 2024-11-14 21:00:00 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001474167 | |||
| revenue | 53376874 | 50347652 | 6.02 |
| gross profit | 4349569 | 5956957 | -26.98 |
| gross profit ratio | 0.08 | 0.12 | -31.13 |
| research and development expenses | 0 | 0 | NaN |
| operating expenses | 25566409 | 13430993 | 90.35 |
| interest income | 662859 | 236349 | 180.46 |
| interest expense | 866476 | 3965248 | -78.15 |
| ebitda | -17061797 | -8901184 | -91.68 |
| ebitdaratio | -0.32 | -0.19 | -69.88 |
| operating income | -21831217 | -7474036 | -192.09 |
| operating income ratio | -0.41 | -0.15 | -175.52 |
| net income | -18542654 | -13830371 | -34.07 |
| net income ratio | -0.35 | -0.27 | -26.46 |
| eps | -2.15 | -7.17 | 70.01 |
Revenue Growth: revenue increased to 53 million in 2023 from 50 million in 2022 representing a change of 6.02%. This indicates a sales growth, which is a positive sign for the company.
Net Income: Net income increased to -19 million in 2023 from -14 million in 2022 representing a change of -34.07%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -2.15 in 2023 from -2.15 in 2022 representing a change of 70.01%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Gross Profit: Gross Profit decreased to 4 million in 2023 from 6 million in 2022 representing a change of -26.98%. This indicates a sales profitability decline, which is a negative sign for the company.
Operating Expenses: Operating Expenses increased to 26 million in 2023 from 13 million in 2022 representing a change of 90.35%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -17 million in 2023 from -9 million in 2022 representing a change of -91.68%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to -22 million in 2023 from -7 million in 2022 representing a change of -192.09%. The decrease in operating income indicates worse operational performance and decreased profitability.
| 2024Q2 | 2024Q1 | Q/Q change % | |
|---|---|---|---|
| 0001474167 | |||
| revenue | 13206717 | 14584473 | -9.45 |
| gross profit | 767248 | 1333626 | -42.47 |
| gross profit ratio | 0.06 | 0.09 | -36.47 |
| research and development expenses | 0 | 0 | NaN |
| operating expenses | 2956200 | 3169734 | -6.74 |
| interest income | 102030 | 105765 | -3.53 |
| interest expense | 342446 | 168672 | 103.02 |
| ebitda | -1935187 | -1378231 | -40.41 |
| ebitdaratio | -0.15 | -0.08 | -75.35 |
| operating income | -2502026 | -1836108 | -36.27 |
| operating income ratio | -0.19 | -0.13 | -50.48 |
| net income | -2590711 | -1866690 | -38.79 |
| net income ratio | -0.2 | -0.13 | -53.26 |
| eps | -0.15 | -0.11 | -36.36 |
Revenue Growth: revenue decreased to 13 million in 2024Q2 from 15 million in 2024Q1 representing a change of -9.45%. This indicates a sales shrinking, which is a negative sign for the company.
Gross Profit: Gross Profit decreased to 1 million in 2024Q2 from 1 million in 2024Q1 representing a change of -42.47%. This indicates a sales profitability decline, which is a negative sign for the company.
Earnings per Share (EPS): EPS increased to -0.15 in 2024Q2 from -0.15 in 2024Q1 representing a change of -36.36%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
Operating Expenses: Operating Expenses decreased to 3 million in 2024Q2 from 3 million in 2024Q1 representing a change of -6.74%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -2 million in 2024Q2 from -1 million in 2024Q1 representing a change of -40.41%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -3 million in 2024Q2 from -2 million in 2024Q1 representing a change of -36.27%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -3 million in 2024Q2 from -2 million in 2024Q1 representing a change of -38.79%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001474167 | |||
| total assets | 66014811 | 68038621 | -2.97 |
| total liabilities | 29971783 | 28381912 | 5.60 |
| total equity | 36043028 | 39656709 | -9.11 |
| cash and cash equivalents | 3833195 | 20749683 | -81.53 |
| short term investments | 20075 | 14881 | 34.90 |
| long term investments | 7214990 | 12553892 | -42.53 |
| total current assets | 36607780 | 56044903 | -34.68 |
| total non current assets | 29407031 | 11993718 | 145.19 |
| total current liabilities | 24322470 | 21748869 | 11.83 |
| total non current liabilities | 5649313 | 6633043 | -14.83 |
| common stock | 15983 | 10606 | 50.70 |
| retained earnings | -91644233 | -66232813 | -38.37 |
| total debt | 12423952 | 12025027 | 3.32 |
Total Assets: Total Assets decreased to 66 million in 2023 from 68 million in 2022 representing a change of -2.97%. Suggesting a decrease in asset holdings.
Total Liabilities: Total Liabilities increased to 30 million in 2023 from 28 million in 2022 representing a change of 5.6%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to 36 million in 2023 from 40 million in 2022 representing a change of -9.11%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 4 million in 2023 from 21 million in 2022 representing a change of -81.53%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 37 million in 2023 from 56 million in 2022 representing a change of -34.68%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 24 million in 2023 from 22 million in 2022 representing a change of 11.83%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -92 million in 2023 from -66 million in 2022 representing a change of -38.37%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 12 million in 2023 from 12 million in 2022 representing a change of 3.32%. This indicates an increase in overall debt burden.
Short Term Investments: Short Term Investments increased to 0 million in 2023 from 0 million in 2022 representing a change of 34.9%. This indicates an increase in short-term investment holdings.
Common Stock: Common Stock increased to 0 in 2023 from 0 in 2022 representing a change of 50.7%. This indicates an increase in ownership interest.
| 2024Q2 | 2024Q1 | Q/Q change % | |
|---|---|---|---|
| 0001474167 | |||
| total assets | 60827344 | 62345195 | -2.43 |
| total liabilities | 28707770 | 27798513 | 3.27 |
| total equity | 32119574 | 34546682 | -7.03 |
| cash and cash equivalents | 343509 | 865099 | -60.29 |
| short term investments | 21509 | 21328 | 0.85 |
| long term investments | 6564083 | 0 | NaN |
| total current assets | 33415128 | 34286943 | -2.54 |
| total non current assets | 27412216 | 28058253 | -2.30 |
| total current liabilities | 24821417 | 23556196 | 5.37 |
| total non current liabilities | 3886352 | 4242317 | -8.39 |
| common stock | 17834 | 17834 | 0.00 |
| retained earnings | -96101634 | -93510923 | -2.77 |
| total debt | 11811976 | 11400411 | 3.61 |
Total Assets: Total Assets decreased to 61 million in 2024Q2 from 62 million in 2024Q1 representing a change of -2.43%. Suggesting a decrease in asset holdings.
Total Liabilities: Total Liabilities increased to 29 million in 2024Q2 from 28 million in 2024Q1 representing a change of 3.27%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to 32 million in 2024Q2 from 35 million in 2024Q1 representing a change of -7.03%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 0 million in 2024Q2 from 1 million in 2024Q1 representing a change of -60.29%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 33 million in 2024Q2 from 34 million in 2024Q1 representing a change of -2.54%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 25 million in 2024Q2 from 24 million in 2024Q1 representing a change of 5.37%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -96 million in 2024Q2 from -94 million in 2024Q1 representing a change of -2.77%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 12 million in 2024Q2 from 11 million in 2024Q1 representing a change of 3.61%. This indicates an increase in overall debt burden.
Short Term Investments: Short Term Investments increased to 0 million in 2024Q2 from 0 million in 2024Q1 representing a change of 0.85%. This indicates an increase in short-term investment holdings.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001474167 | |||
| net change in cash | -16916488 | 20463196 | -182.67 |
| operating cash flow | -15635999 | -14870639 | -5.15 |
| free cash flow | -23856646 | -15253712 | -56.40 |
| capital expenditure | -9167759 | -383073 | -2293.21 |
| depreciation and amortization | 614377 | 188890 | 225.26 |
| deferred income tax | 78553 | 780099 | -89.93 |
| stock based compensation | 577931 | 24401 | 2268.47 |
| accounts payables | 716615 | 1734423 | -58.68 |
| inventory | -890903 | -485469 | -83.51 |
| acquisitions net | -5230593 | 12736 | -41169.35 |
| investments in property plant and equipment | -2978195 | -383073 | -677.45 |
| net cash used for investing activites | -13760357 | -21497 | -63910.59 |
| debt repayment | -21412 | -13858487 | 99.85 |
| common stock issued | 10000017 | 35275573 | -71.65 |
| common stock repurchased | -100452 | 0 | NaN |
| dividends paid | 0 | -32004730 | 100.00 |
| net cash used provided by financing activities | 12694007 | 35048288 | -63.78 |
| cash at end of period | 3833195 | 20749683 | -81.53 |
| accounts receivables | -4026367 | -3244181 | -24.11 |
| cash at beginning of period | 20749683 | 286487 | 7142.80 |
Net Change in Cash: Net Change in Cash decreased to -17 million in 2023 from 20 million in 2022 representing a change of -182.67%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to -16 million in 2023 from -15 million in 2022 representing a change of -5.15%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -24 million in 2023 from -15 million in 2022 representing a change of -56.4%. This indicates a decrease in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation increased to 1 million in 2023 from 0 million in 2022 representing a change of 2268.47%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Capital Expenditure: Capital Expenditure decreased to -9 million in 2023 from 0 million in 2022 representing a change of -2293.21%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Accounts Payables: The absolute value of Accounts Payables decreased to 1 million in 2023 from 2 million in 2022 representing a change of -58.68%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables decreased to -4 million in 2023 from -3 million in 2022 representing a change of -24.11%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
Dividends Paid: Dividends Paid increased to 0 million in 2023 from -32 million in 2022 representing a change of 100.0%. This indicates a stronger financial position, more confidence in future prospects, and a better commitment to returning value to shareholders.
| 2024Q2 | 2024Q1 | Q/Q change % | |
|---|---|---|---|
| 0001474167 | |||
| operating cash flow | -1210886 | -3412103 | 64.51 |
| free cash flow | -1245050 | -3494765 | 64.37 |
| capital expenditure | -34164 | -82662 | 58.67 |
| depreciation and amortization | 313074 | 319787 | -2.10 |
| deferred income tax | -1301 | -4344 | 70.05 |
| stock based compensation | 340195 | 340194 | 0.00 |
| accounts receivables | 339064 | -110614 | 406.53 |
| accounts payables | 188852 | -279448 | 167.58 |
| inventory | 519456 | -196020 | 365.00 |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -34164 | -82662 | 58.67 |
| net cash used for investing activites | 115950 | 126454 | -8.31 |
| debt repayment | 539666 | -422632 | 227.69 |
| common stock issued | -649039 | 649039 | -200.00 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 539668 | 206942 | 160.78 |
| net change in cash | -521590 | -2968096 | 82.43 |
| cash at end of period | 343509 | 865099 | -60.29 |
| cash at beginning of period | 865099 | 3833195 | -77.43 |
Net Change in Cash: Net Change in Cash increased to -1 million in 2024Q2 from -3 million in 2024Q1 representing a change of 82.43%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to -1 million in 2024Q2 from -3 million in 2024Q1 representing a change of 64.51%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -1 million in 2024Q2 from -3 million in 2024Q1 representing a change of 64.37%. This indicates an increase in cash generated after accounting for capital expenditures.
Accounts Payables: The absolute value of Accounts Payables decreased to 0 million in 2024Q2 from 0 million in 2024Q1 representing a change of 167.58%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Capital Expenditure: Capital Expenditure increased to 0 million in 2024Q2 from 0 million in 2024Q1 representing a change of 58.67%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Deferred Income Tax: Deferred Income Tax increased to 0 million in 2024Q2 from 0 million in 2024Q1 representing a change of 70.05%. This indicates that the company's tax liability for future periods has increased.
Stock-Based Compensation: Stock-Based Compensation increased to 0 million in 2024Q2 from 0 million in 2024Q1 representing a change of 0.0%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Receivables: Accounts Receivables increased to 0 in 2024Q2 from 0 million in 2024Q1 representing a change of 406.53%. This suggests that the company is less capable of collecting payments from its customers.
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 4.46 | 26.11 | -82.92 |
| net income per share | -1.55 | -7.17 | 78.40 |
| operating cash flow per share | -1.31 | -7.71 | 83.06 |
| free cash flow per share | -1.99 | -7.91 | 74.80 |
| cash per share | 0.32 | 10.77 | -97.01 |
| book value per share | 3.01 | 20.57 | -85.36 |
| tangible book value per share | 2.37 | 20.2 | -88.27 |
| shareholders equity per share | 3.01 | 20.57 | -85.36 |
| interest debt per share | 1.01 | 7.71 | -86.86 |
| market cap | 16875817.65 | 8792464.32 | 91.94 |
| enterprise value | 25466574.65 | 67808.32 | 37456.71 |
| pe ratio | -0.91 | -0.64 | -43.16 |
| price to sales ratio | 0.32 | 0.17 | 81.04 |
| pocfratio | -1.08 | -0.59 | -82.54 |
| pfcf ratio | -0.71 | -0.58 | -22.72 |
| pb ratio | 0.47 | 0.22 | 111.18 |
| ptb ratio | 0.47 | 0.22 | 111.18 |
| ev to sales | 0.48 | 0.0 | 35325.31 |
| enterprise value over ebitda | -1.49 | -0.01 | -19493.43 |
| ev to operating cash flow | -1.63 | -0.0 | -35618.36 |
| ev to free cash flow | -1.07 | -0.0 | -23913.40 |
| earnings yield | -1.1 | -1.57 | 30.15 |
| free cash flow yield | -1.41 | -1.73 | 18.51 |
| debt to equity | 0.31 | 0.27 | 13.67 |
| debt to assets | 0.17 | 0.16 | 6.48 |
| net debt to ebitda | -0.5 | 0.98 | -151.37 |
| current ratio | 1.51 | 2.58 | -41.59 |
| interest coverage | -25.2 | -1.88 | -1236.71 |
| income quality | 0.84 | 1.08 | -21.57 |
| dividend yield | 0 | 3.64 | -100.00 |
| payout ratio | 0 | -2.31 | 100.00 |
| sales general and administrative to revenue | 0.46 | 0.25 | 82.20 |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0.12 | 0.01 | 1020.33 |
| capex to operating cash flow | -0.59 | -0.03 | -2176.07 |
| capex to revenue | 0.17 | 0.01 | 2157.40 |
| capex to depreciation | 14.92 | 2.03 | 635.79 |
| stock based compensation to revenue | 0.01 | 0.0 | 2134.06 |
| graham number | 10.25 | 57.61 | -82.22 |
| roic | -0.46 | -0.16 | -194.69 |
| return on tangible assets | -0.32 | -0.21 | -54.76 |
| graham net net | -0.74 | 5.8 | -112.83 |
| working capital | 12285310 | 34296034 | -64.18 |
| tangible asset value | 28358845 | 38949795 | -27.19 |
| net current asset value | 6635997 | 27662991 | -76.01 |
| invested capital | 31585334 | 37932804 | -16.73 |
| average receivables | 21260622 | 26449497 | -19.62 |
| average payables | 11023062 | 11429948.5 | -3.56 |
| average inventory | 4120461 | 3299572 | 24.88 |
| days sales outstanding | 135.12 | 165.02 | -18.12 |
| days payables outstanding | 88.68 | 83.33 | 6.43 |
| days of inventory on hand | 35.65 | 28.38 | 25.62 |
| receivables turnover | 2.7 | 2.21 | 22.13 |
| payables turnover | 4.12 | 4.38 | -6.04 |
| inventory turnover | 10.24 | 12.86 | -20.39 |
| roe | -0.51 | -0.35 | -47.51 |
| capex per share | 0.77 | 0.2 | 285.55 |
ROE: Return on Equity (ROE) decreased to -0.51 on 2023-12-31 from -0.35 on 2022-12-31, representing a change of -47.51%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -0.91 on 2023-12-31 from -0.64 on 2022-12-31, representing a change of -43.16%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 1.51 on 2023-12-31 from 2.58 on 2022-12-31, representing a change of -41.59%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. However, it is still above 1, indicating the ability to cover short-term obligations.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.31 on 2023-12-31 from 0.27 on 2022-12-31, representing a change of 13.67%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-06-30 Q2 | 2024-03-31 Q1 | Q/Q change % | |
|---|---|---|---|
| COSM | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0.74 | 0.87 | -14.43 |
| net income per share | -0.15 | -0.11 | -31.14 |
| operating cash flow per share | -0.07 | -0.2 | 66.47 |
| free cash flow per share | -0.07 | -0.21 | 66.34 |
| cash per share | 0.02 | 0.05 | -61.09 |
| book value per share | 1.8 | 2.05 | -12.15 |
| tangible book value per share | 1.37 | 1.58 | -13.26 |
| shareholders equity per share | 1.8 | 2.05 | -12.15 |
| interest debt per share | 0.64 | 0.64 | 0.11 |
| market cap | 19617425.3 | 11796222.9 | 66.30 |
| enterprise value | 31085892.3 | 22331534.9 | 39.20 |
| pe ratio | -1.89 | -1.58 | -19.83 |
| price to sales ratio | 1.49 | 0.81 | 83.65 |
| pocfratio | -16.2 | -3.46 | -368.62 |
| pfcf ratio | -15.76 | -3.38 | -366.80 |
| pb ratio | 0.61 | 0.34 | 78.87 |
| ptb ratio | 0.61 | 0.34 | 78.87 |
| ev to sales | 2.35 | 1.53 | 53.72 |
| enterprise value over ebitda | -16.06 | -16.2 | 0.86 |
| ev to operating cash flow | -25.67 | -6.54 | -292.25 |
| ev to free cash flow | -24.97 | -6.39 | -290.73 |
| earnings yield | -0.13 | -0.16 | 16.55 |
| free cash flow yield | -0.06 | -0.3 | 78.58 |
| debt to equity | 0.34 | 0.31 | 12.29 |
| debt to assets | 0.18 | 0.17 | 7.00 |
| net debt to ebitda | -5.93 | -7.64 | 22.47 |
| current ratio | 1.35 | 1.46 | -7.51 |
| interest coverage | -7.31 | -10.89 | 32.88 |
| income quality | 0.47 | 1.83 | -74.43 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.22 | 0.18 | 17.41 |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0.13 | 0.13 | -0.68 |
| capex to operating cash flow | -0.03 | -0.02 | -16.46 |
| capex to revenue | 0.0 | 0.01 | -54.36 |
| capex to depreciation | 0.11 | 0.26 | -57.78 |
| stock based compensation to revenue | 0.03 | 0.02 | 10.43 |
| graham number | 2.43 | 2.26 | 7.34 |
| roic | -0.06 | -0.05 | -19.40 |
| return on tangible assets | -0.05 | -0.03 | -42.11 |
| graham net net | -0.59 | -0.5 | -17.30 |
| working capital | 8593711 | 10730747 | -19.92 |
| tangible asset value | 24403332 | 26583773 | -8.20 |
| net current asset value | 4707358 | 6488430 | -27.45 |
| invested capital | 27119803 | 31673418 | -14.38 |
| average receivables | 21098655.5 | 20543291.5 | 2.70 |
| average payables | 10989845 | 11495992 | -4.40 |
| average inventory | 4597566.5 | 4830201.5 | -4.82 |
| days sales outstanding | 142.22 | 131.61 | 8.06 |
| days payables outstanding | 78.86 | 75.26 | 4.79 |
| days of inventory on hand | 31.28 | 33.09 | -5.45 |
| receivables turnover | 0.63 | 0.68 | -7.46 |
| payables turnover | 1.14 | 1.2 | -4.57 |
| inventory turnover | 2.88 | 2.72 | 5.77 |
| roe | -0.08 | -0.05 | -49.27 |
| capex per share | 0.0 | 0.0 | -60.95 |
ROE: Return on Equity (ROE) decreased to -0.08 on 2024-06-30 Q2 from -0.05 on 2024-03-31 Q1, representing a change of -49.27%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -1.89 on 2024-06-30 Q2 from -1.58 on 2024-03-31 Q1, representing a change of -19.83%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 1.35 on 2024-06-30 Q2 from 1.46 on 2024-03-31 Q1, representing a change of -7.51%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. However, it is still above 1, indicating the ability to cover short-term obligations.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.34 on 2024-06-30 Q2 from 0.31 on 2024-03-31 Q1, representing a change of 12.29%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
None
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2024-11-12 12:00:00
CHICAGO, IL / ACCESSWIRE / November 12, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its Chief Executive Officer, Greg Siokas, has issued the following letter to the Company's shareholders. Dear Cosmos Health Shareholders, It has been just over a year since my previous shareholder letter, and I would like to express my sincere gratitude for your continued support.
Sentiment: Positive
Publish Date: 2024-11-01 12:30:00
CHICAGO, IL / ACCESSWIRE / November 1, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its healthcare distribution business, operated through its wholly owned subsidiary, CosmoFarm S.A. ("CosmoFarm"), has achieved record sales.
Sentiment: Positive
Publish Date: 2024-09-25 09:25:00
CHICAGO, IL / ACCESSWIRE / September 25, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that sales of its proprietary brands, including Sky Premium Life, on Amazon in the United Kingdom have surged by 160%, increasing to $596,000 year-to-date in 2024 from $230,000 during the same period in 2023. Greg Siokas, CEO of Cosmos Health, stated: "We are delighted that our proprietary brands are being very well received by UK consumers, achieving impressive growth.
Sentiment: Positive
Publish Date: 2024-09-23 12:55:00
CHICAGO, IL / ACCESSWIRE / September 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has received its first round of purchase orders in the United Kingdom (UK) for its antimicrobial wash, C-Scrub Wash Chlorhexidine 4% ('C-Scrub'), exceeding $500,000. The orders cover the period from July 2024 to September 2024.
Sentiment: Positive
Publish Date: 2024-09-23 09:00:00
CHICAGO, IL / ACCESSWIRE / September 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered into an exclusivity agreement with Virax Biolabs to distribute mpox (formerly monkeypox) virus real-time PCR detection kits across India. With a population of over 1.4 billion, India is an important region where enhanced detection capabilities are needed.
Sentiment: Positive
Publish Date: 2024-09-19 15:40:00
CHICAGO, IL / ACCESSWIRE / September 19, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered the development phase for CCDL24, an innovative treatment for gastrointestinal (GI) disorders. CCDL24 leverages advanced biopolymeric grids derived from natural ingredients to encapsulate bioactive molecules, extending their activity at the targeted site and ultimately enhancing drug efficacy.
Sentiment: Positive
Publish Date: 2024-09-18 13:30:00
CHICAGO, IL / ACCESSWIRE / September 18, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today its updated guidance for the 2024-2027 period. Key highlights of the guidance include: Revenue is projected to increase by 163%, from $59.35 million in 2024 to $155.80 million in 2027.
Sentiment: Positive
Publish Date: 2024-09-16 08:30:00
LONDON , Sept. 16, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that it has entered into an extension of its already existing exclusive distribution agreement with Cosmos Health Inc. (Nasdaq: COSM) ("Cosmos") to commercialize Mpox Virus Real-Time PCR Detection Kits in countries in the Gulf Cooperation Council ("GCC").
Sentiment: Positive
Publish Date: 2024-09-16 08:30:00
CHICAGO, IL / ACCESSWIRE / September 16, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered into an extension of its existing exclusive distribution agreement with Virax Biolabs (NASDAQ: VRAX) to commercialize mpox virus real-time PCR detection kits in countries within the Gulf Cooperation Council ("GCC"). It had previously signed an agreement for exclusive distribution in Greece and Cyprus, as well as for non-exclusive distribution throughout Europe.
Sentiment: Positive
Publish Date: 2024-08-23 09:35:00
CHICAGO, IL / ACCESSWIRE / August 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that the Company has regained compliance with Listing Rule 5250(c)(1) (the "Filing Rule"), in connection with the filing of its 2023 Annual Report on Form 10-K (the "Annual Report") and its financial results for the first quarter ended March 31, 2024, on Form 10-Q (the "First Quarter Report"). On April 17 and May 21, 2024, the Company received notification letters (the "Notification Letters") from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") stating that it no longer met the periodic filing requirement for The Nasdaq Stock Market Filing Rule.
Sentiment: Positive
Publish Date: 2024-08-21 10:20:00
CHICAGO, IL / ACCESSWIRE / August 21, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today, pursuant to its agreement with Virax Biolabs (NASDAQ: VRAX), that it continues to hold the rights to distribute mpox virus real-time PCR detection kits, with exclusive distribution rights in Greece and Cyprus, and non-exclusive distribution rights across Europe. On August 14, 2024, World Health Organization (WHO) Director-General Dr. Tedros Adhanom Ghebreyesus determined that the upsurge of mpox in the Democratic Republic of the Congo and a growing number of countries in Africa constitutes a public health emergency of international concern under the International Health Regulations.
Sentiment: Positive
Publish Date: 2024-08-20 12:20:00
CHICAGO, IL / ACCESSWIRE / August 20, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today reported financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights Income Statement: Revenue increased by 6.8%, or $0.84 million, to $13.21 million in Q2 2024, up from $12.36 million in Q2 2023, driven by a combination of organic growth and recent M&A activity.
Sentiment: Positive
Publish Date: 2024-08-20 09:00:00
CHICAGO, IL / ACCESSWIRE / August 20, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Highlights Income Statement: Revenue increased by 18.1%, or $2.23 million, to $14.58 million in Q1 2024, up from $12.35 million in Q1 2023, driven by organic growth and the positive impact of 2023 M&A activity.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
